Private faricimab (Vabysmo) wet AMD injection cost UK 2026

What is faricimab (Vabysmo)?

Faricimab (Vabysmo, Roche, formerly RG7716) is a humanised bispecific monoclonal antibody (CrossMAb format) that simultaneously binds and neutralises two distinct cytokines driving macular neovascularisation, leakage and inflammation: vascular endothelial growth factor A (VEGF-A) and angiopoietin-2 (Ang-2). VEGF-A is the master regulator of pathological angiogenesis and macular vascular permeability and is the target of all the established intravitreal anti-VEGF agents (aflibercept, ranibizumab, bevacizumab, brolucizumab). Ang-2 is a Tie2-receptor antagonist that destabilises the existing vasculature, sensitises endothelial cells to VEGF-A and amplifies inflammatory signalling; in wet AMD, DMO and RVO, Ang-2 is over-expressed and contributes to chronic leakage, pericyte loss and inflammation. Faricimab is the first and currently only intravitreal therapy that targets both VEGF-A and Ang-2, and the dual mechanism is the biological basis for its ability to extend the treatment interval safely to up to 16 weeks (Q16, every 4 months) in approximately 60 per cent of patients by year 2 in TENAYA and LUCERNE.

Faricimab is supplied as a single-use sterile glass vial containing 6 mg / 0.05 mL. It is administered as a day-case intravitreal injection through the pars plana (3.5 mm posterior to the limbus in pseudophakic eyes, 4.0 mm in phakic eyes) under topical anaesthetic with povidone iodine surface preparation and a sterile drape, in a clean-room or sterile minor procedure room. The injection itself takes seconds; the total visit (vision testing, IOP, slit-lamp, OCT macula, the injection and immediate post-injection check) takes 60 to 90 minutes.

The licensed schedule for wet AMD is 4 monthly loading doses (one injection per month for the first 4 months), followed by a treat-and-extend protocol where the interval between injections is extended by 4 weeks at a time if the OCT macula is dry and the BCVA is stable, and shortened by 4 weeks if there is recurrent fluid or visual decline. Intervals run from Q8 (every 8 weeks) up to Q16 (every 16 weeks). For diabetic macular oedema (DMO) and macular oedema secondary to retinal vein occlusion (BRVO, CRVO) the loading schedule and treat-and-extend approach are similar, with disease-specific NICE guidance.

UK 2026 faricimab (Vabysmo) pricing, in detail

UK 2026 faricimab pricing varies with the centre overhead, the drug procurement cost (the list price of a single Vabysmo 6 mg vial is typically 600 to 850 pounds before NHS or hospital procurement rebate), the seniority of the medical retina consultant, the imaging included (OCT alone vs OCT plus OCT angiography vs OCT plus OCT-A plus FFA / ICG), and the post-injection monitoring schedule. The fee should be quoted as an all-inclusive per-injection package and an itemised year-1 and maintenance-year budget should be provided.

For related medical retina pricing see our private anti-VEGF wet AMD injections overview, our wet AMD condition guide, our dry AMD guide and our wet vs dry AMD treatment options 2026.

What should be included in a private faricimab package in the UK in 2026?

• Medical retina consultant — a UK GMC specialist registered consultant ophthalmologist with documented medical retina fellowship, doing a high volume of intravitreal anti-VEGF therapy (typically 1,000 or more injections per year), with audit data on per-injection endophthalmitis rate (target less than 0.05 per cent), intra-ocular inflammation rate and 1-year and 2-year BCVA outcomes available on request.
• Full medical retina work-up — best corrected visual acuity (logMAR / ETDRS), IOP, slit-lamp dilated fundus examination, swept-source or spectral-domain OCT macula (5-line raster, dense raster, en-face, RPE / retinal segmentation), OCT angiography for the neovascular complex, fundus fluorescein angiography (FFA) where indicated for atypical presentation, indocyanine green angiography (ICG) for suspected polypoidal choroidal vasculopathy (PCV) or retinal angiomatous proliferation (RAP).
• Indication confirmation — neovascular (wet) age-related macular degeneration on OCT and OCT-A (intra-retinal fluid, sub-retinal fluid, pigment epithelial detachment, type 1 / 2 / 3 neovascular complex); diabetic macular oedema with central retinal thickness greater than the OCT-defined threshold and BCVA criteria per NICE TA799; macular oedema secondary to BRVO or CRVO with similar OCT and BCVA criteria.
• Treatment plan — treatment-naive patients: 4 monthly faricimab loading doses then treat-and-extend Q8 up to Q16. Switch patients (from aflibercept 2 mg, ranibizumab) unable to extend: 1 to 2 monthly faricimab loading doses then treat-and-extend. Personalised on prior treatment response and OCT phenotype.
• Day-case clean-room intravitreal injection — topical anaesthetic, povidone iodine surface preparation, sterile drape and lid speculum, pars plana 30-gauge injection at 3.5 mm (pseudophakic) or 4.0 mm (phakic) posterior to the limbus, immediate post-injection IOP and vision check.
• Post-injection care — topical antibiotic (e.g. chloramphenicol four times a day for 24 to 48 hours, per local protocol), 7-day endophthalmitis symptom warning (sudden pain, severe redness, vision loss, floaters, photophobia), 24/7 contact details.
• Treat-and-extend OCT decision-making — at each subsequent visit, OCT macula determines extend / treat-as-before / shorten; the aim is to reach the longest interval at which the macula remains dry and the BCVA stable.
• CQC-registered clean-room or sterile minor procedure room with the latest report rated Good or Outstanding; transparent itemised written pricing; direct telephone access to the consultant for the duration of treatment.
• Honest evidence-based consent — written information about per-injection endophthalmitis (0.02 to 0.05 per cent), intra-ocular inflammation (1 to 2 per cent per patient course), rare retinal vasculitis with occlusion, the treat-and-extend rationale and the realistic year-1 and maintenance-year treatment burden.

What does the evidence say about faricimab?

The faricimab evidence base is among the strongest of any modern intravitreal therapy and is consistent across indications:

• TENAYA and LUCERNE phase 3 wet AMD trials (Heier et al., Lancet 2022) — identical-design randomised non-inferiority trials of treatment-naive neovascular AMD, faricimab 6 mg with treat-and-extend up to Q16 after 4 monthly loading doses vs aflibercept 2 mg Q8 after 3 monthly loading doses. Primary endpoint mean BCVA change at year 1: ~+6 ETDRS letters in both arms, non-inferior. At year 2: approximately 60 per cent of faricimab patients on Q12 or Q16, with maintained BCVA gains and a substantially lower treatment burden than aflibercept 2 mg.
• YOSEMITE and RHINE phase 3 DMO trials (Wykoff et al., Lancet 2022) — identical-design randomised non-inferiority trials in DMO, faricimab 6 mg with treat-and-extend up to Q16 vs aflibercept 2 mg Q8. Non-inferior BCVA outcomes at year 1; approximately 50 to 60 per cent of faricimab patients on Q12 or Q16 by year 2; substantial reduction in central retinal thickness.
• BALATON and COMINO phase 3 RVO trials (2024) — faricimab non-inferior to aflibercept 2 mg in macular oedema secondary to BRVO and CRVO at year 1; extended dosing in a substantial proportion of patients.
• AVONELLE-X and RHONE-X open-label extension studies — sustained BCVA gains and durable treatment intervals through years 2 to 4 in wet AMD and DMO respectively.
• NICE Technology Appraisals TA800 (wet AMD) and TA799 (DMO) — both recommend faricimab as an option for treating the licensed indications, within the marketing authorisation. Subsequent NICE guidance covers macular oedema secondary to BRVO and CRVO.
• Royal College of Ophthalmologists wet AMD commissioning guidance — faricimab and aflibercept 8 mg are the preferred first-line options for treatment-naive wet AMD in 2025 to 2026, on the basis of lower year-2 treatment burden than aflibercept 2 mg, ranibizumab or bevacizumab while maintaining equivalent BCVA outcomes.
• Real-world evidence (Truckenbrod 2024, MEEP / IRIS Registry 2024 to 2025, AAO 2024 / 2025) — faricimab effective in routine clinical practice with comparable BCVA outcomes to trial data and lower treatment burden; effective as a switch agent in patients unable to extend on aflibercept 2 mg or ranibizumab.
• Safety — integrated safety database across TENAYA / LUCERNE / YOSEMITE / RHINE / BALATON / COMINO shows endophthalmitis rate 0.02 to 0.05 per cent per injection (in line with all modern anti-VEGFs with povidone iodine prep), intra-ocular inflammation 1 to 2 per cent per patient course, retinal vasculitis with occlusion rare and at lower frequency than brolucizumab (Beovu).
• Cost-effectiveness (NICE) — faricimab is cost-effective at NHS list price net of the confidential commercial discount, on the basis of lower year-2 treatment burden offsetting the per-injection drug cost.

In short: faricimab is one of the best-evidenced and most clinically refined intravitreal therapies for wet AMD, DMO and RVO in 2026, with strong randomised and real-world data on BCVA, treatment burden and safety, and a unique dual VEGF-A / Ang-2 mechanism that allows safe extension of the treatment interval in a meaningful proportion of patients.

Faricimab vs aflibercept 2 mg / 8 mg, ranibizumab, brolucizumab and bevacizumab

Each modern intravitreal anti-VEGF agent has a defined 2026 indication and treatment-burden profile:

• Faricimab (Vabysmo, Roche) — 6 mg bispecific VEGF-A and Ang-2 antibody; 4 monthly loading doses then treat-and-extend Q8 up to Q16. Lowest year-2 treatment burden among anti-VEGFs in TENAYA / LUCERNE / YOSEMITE / RHINE / BALATON / COMINO. NICE TA800 / TA799. Per injection UK 2026 1,100 to 1,650 pounds.
• Aflibercept 8 mg (Eylea HD, Regeneron / Bayer) — high-dose VEGF-A plus PlGF fusion protein; 3 monthly loading doses then Q12 or Q16 by treat-and-extend. Comparable BCVA and treatment-burden profile to faricimab in PULSAR / PHOTON. Per injection UK 2026 1,200 to 1,750 pounds.
• Aflibercept 2 mg (Eylea, Regeneron / Bayer) — VEGF-A plus PlGF fusion protein; 3 monthly loading doses then Q8 or treat-and-extend. Established gold standard with the largest cumulative clinical experience. Per injection UK 2026 900 to 1,400 pounds. Biosimilars in development.
• Ranibizumab (Lucentis, Novartis / Genentech) — 0.5 mg VEGF-A antibody fragment; 3 monthly loading then PRN or treat-and-extend. Multiple biosimilars (Ongavia, Ranivisio, Byooviz). Per injection UK 2026 850 to 1,300 pounds. Also available as a port delivery system (Susvimo, surgically implanted refillable reservoir with 6-monthly refills).
• Brolucizumab (Beovu, Novartis) — 6 mg single-chain antibody fragment; 3 monthly loading then Q8 / Q12. Highest molar dose; more compact molecule allowing higher vitreous concentration. Associated with a measurable risk of intra-ocular inflammation including retinal vasculitis with occlusion (HAWK / HARRIER post-hoc analyses); use is more selective in 2026. Per injection UK 2026 1,000 to 1,450 pounds.
• Bevacizumab (Avastin, Roche) — off-label VEGF-A antibody re-packaged from oncology vials; widely used in NHS hospital eye services on a cost-effectiveness basis where local commissioning permits. Comparable BCVA to ranibizumab in CATT and IVAN. Not licensed for intravitreal use in the UK.

The decision between faricimab, aflibercept 2 mg / 8 mg, ranibizumab and brolucizumab is shared with the consultant medical retinologist on the basis of the indication, the patient's prior treatment history (treatment-naive vs switch), the anticipated treatment burden, intra-ocular inflammation risk, comorbidities, the local NHS / private commissioning landscape and patient preference. For treatment-naive wet AMD, faricimab and aflibercept 8 mg are commonly first-line for the lowest year-2 burden; for switch patients unable to extend on aflibercept 2 mg or ranibizumab, faricimab is a logical choice on the basis of the dual mechanism.

Who is a good candidate for faricimab?

The strongest case for faricimab applies when one or more of the following are present:

• Newly diagnosed treatment-naive neovascular (wet) age-related macular degeneration — with active intra-retinal fluid, sub-retinal fluid or pigment epithelial detachment on OCT macula and a confirmed neovascular complex on OCT angiography or FFA, in an eye with viable macular function (no established subretinal fibrosis or macular atrophy precluding visual benefit).
• Diabetic macular oedema (DMO) — with central macular thickness above the NICE TA799 threshold and BCVA criteria, in a patient with controlled or controllable systemic diabetes; faricimab is licensed and NICE-approved on the basis of YOSEMITE / RHINE.
• Macular oedema secondary to branch or central retinal vein occlusion (BRVO, CRVO) — on the basis of BALATON / COMINO.
• Patients already on aflibercept 2 mg, ranibizumab or bevacizumab unable to extend safely — with recurrent intra-retinal or sub-retinal fluid at intervals of Q4 to Q6 despite optimisation; real-world evidence shows 40 to 60 per cent can extend safely on faricimab.
• Polypoidal choroidal vasculopathy (PCV) — faricimab is effective off-label / case-by-case in PCV, on the basis of small series and consensus statements; ICG imaging is essential.
• Motivation for the lowest possible treatment burden — for working-age patients, distant-living patients, patients with mobility limitations or those with strong preferences for fewer hospital visits per year.
• No active ocular infection, no active uveitis, no recent arterial thromboembolic event, no known hypersensitivity to faricimab.
• Ability to attend and tolerate intravitreal injection and OCT-driven follow-up.

Faricimab is not appropriate in active ocular or peri-ocular infection, active uveitis or endophthalmitis, known hypersensitivity to faricimab, pregnancy / breastfeeding (no safety data), recent arterial thromboembolic event (within 3 months) on a case-by-case basis, or where the macula is end-stage with established subretinal fibrosis or macular atrophy and no prospect of visual benefit. Suitability is always confirmed at a consultant medical retina consultation with OCT and OCT angiography.

NHS vs private faricimab in the UK 2026

NHS access to faricimab in the UK in 2026 is well-established. NICE Technology Appraisal TA800 recommends faricimab as an option for neovascular AMD, TA799 covers DMO, and further NICE guidance covers macular oedema secondary to BRVO and CRVO. Faricimab is commissioned via NHS England (and equivalent pathways in Scotland, Wales and Northern Ireland) and delivered through hospital eye service medical retina clinics in structured 4 to 16 weekly treat-and-extend pathways. Realistic NHS waits for the first injection after wet AMD diagnosis are typically 1 to 4 weeks in 2026; faster fast-track pathways exist for patients with high-risk presentations. NHS care is excellent and the only practical limitations are the timing of the first injection, choice of consultant and the breadth of imaging available at the local trust.

Private faricimab in the UK is the practical route when same-week initiation matters (for example, rapidly progressing wet AMD with active fluid in a fellow eye), when you want a specific consultant medical retinologist or a specific clinic, when you have private medical insurance that covers the procedure, or when local NHS pressures mean a delayed first injection beyond a clinically acceptable window. Most CQC-registered London medical retina centres can complete consultation, OCT, OCT angiography and the first faricimab injection within 5 to 7 days.

Does private medical insurance cover faricimab?

In 2026 the major UK private medical insurers (Bupa, AXA Health, Aviva, Vitality, WPA) cover faricimab for licensed indications when there is a documented diagnosis on OCT, OCT angiography (where appropriate) and consultant medical retina assessment: neovascular (wet) AMD with active intra-retinal or sub-retinal fluid, DMO with central retinal thickness above threshold and BCVA criteria, macular oedema secondary to BRVO or CRVO. Coverage typically includes the consultant fee, OCT imaging, the injection procedure, the drug itself and immediate post-injection follow-up.

Pre-authorisation in writing is required and should specify the indication, the planned schedule (4 monthly loading doses then treat-and-extend) and the expected number of injections in year 1. Maintenance-year cover is normally provided on an annual policy basis and may require a renewed pre-authorisation each year. Insurers generally do not cover faricimab for off-label indications outside the licensed scope, for screening, for end-stage disease with no realistic prospect of visual benefit, or for procedures performed outside CQC-registered private healthcare premises. The clinical letter must document the diagnosis, BCVA, central retinal thickness, OCT findings (intra-retinal fluid, sub-retinal fluid, PED), OCT-A findings (the neovascular complex), the prior treatment history (if any) and the rationale for faricimab specifically.

Risks and side-effects of faricimab

Intravitreal faricimab is one of the safest interventional ocular procedures, but it is intra-ocular injection of a biologic and the realistic risks should be set out honestly:

• Procedural risks (any intravitreal injection):
  • Endophthalmitis — 0.02 to 0.05 per cent per injection with povidone iodine prep and sterile technique; severe sight-threatening intra-ocular infection. Prevented by povidone iodine surface preparation, sterile drape, lid speculum, no-touch technique and the 7-day post-injection symptom warning (sudden pain, severe redness, vision loss, floaters, photophobia).
  • Traumatic cataract — less than 0.1 per cent per injection; caused by inadvertent lens contact.
  • Retinal detachment — less than 0.05 per cent per injection; presents with new floaters and a curtain over the vision.
  • Vitreous haemorrhage — less than 0.1 per cent per injection; usually self-limiting.
  • Subconjunctival haemorrhage — very common, cosmetic only, resolves in 1 to 2 weeks.
  • Transient IOP spike — very common immediately post-injection, usually resolves within 30 minutes; treated with topical IOP-lowering medication if needed.
  • Transient blurred vision / floaters — from the injection bubble / dispersal of the drug in the vitreous; resolves within 24 to 48 hours.
• Drug-specific risks (faricimab):
  • Intra-ocular inflammation (IOI) — 1 to 2 per cent per patient course; usually mild anterior chamber inflammation responding to topical steroid. Rare cases of retinal vasculitis with occlusion have been reported but at lower frequency than brolucizumab (Beovu).
  • Allergic / hypersensitivity reactions — rare; require discontinuation.
  • Increased IOP (chronic) — possible with cumulative intravitreal injections; managed with topical IOP-lowering drops if needed.
• Systemic anti-VEGF risks (arterial thromboembolic events) — very low with intravitreal administration because of minimal systemic exposure; honest part of consent in patients with recent stroke or myocardial infarction.
• Treatment burden — lifelong intravitreal therapy with OCT monitoring at each visit. Most patients require 4 to 8 injections per year on treat-and-extend, falling over time.

The overall safety record of faricimab is excellent in experienced UK hands; the procedural risks are minimised by povidone iodine prep, sterile technique and adherence to the 7-day post-injection symptom warning; the drug-specific intra-ocular inflammation rate is favourable; the realistic year-1 and maintenance-year treatment burden is lower than with VEGF-A monotherapy.

What to expect after a faricimab injection and the treat-and-extend pathway

• Immediately after the injection — mild grittiness, transient blurred vision, floaters from the injection bubble. Subconjunctival haemorrhage at the injection site is common, cosmetic only. Topical antibiotic for 24 to 48 hours.
• First 7 days — vigilant for endophthalmitis symptoms (sudden pain, severe redness, vision loss, floaters, photophobia); if any develop, contact the clinic urgently and be seen the same day. Otherwise, no specific posturing or activity restriction.
• Loading phase (months 1 to 4) — 4 monthly injections. Most patients notice a partial improvement in distortion and central vision within 1 to 4 weeks of the first injection, with progressive macular drying on OCT over the first 4 to 12 weeks.
• Treat-and-extend (month 5 onwards) — at each visit, OCT macula determines extend / treat-as-before / shorten:
  • Dry macula and stable BCVA — extend the interval by 4 weeks (up to Q16 maximum).
  • Borderline / stable — continue at current interval.
  • Recurrent fluid or visual decline — shorten the interval by 4 weeks (minimum Q8).
• Year 1 outcomes — mean BCVA gain ~+5 to +6 ETDRS letters from baseline; stable or improved BCVA in 80 to 90 per cent of patients; mean central retinal thickness reduction ~150 to 200 microns from baseline.
• Year 2 and beyond — approximately 60 per cent of TENAYA / LUCERNE patients on Q12 or Q16 dosing; sustained BCVA gains in the AVONELLE-X / RHONE-X extension studies through years 2 to 4.
• Long-term monitoring — OCT at every visit. A small proportion of patients (perhaps 5 to 10 per cent) achieve long-lasting remission and can pause treatment with 3-monthly OCT surveillance. Stopping without monitoring is associated with a high risk of vision loss.
• If treatment fails — if faricimab does not control the disease (persistent fluid at Q4 to Q6 despite optimisation), the consultant may switch to aflibercept 8 mg (Eylea HD), aflibercept 2 mg (Eylea) or to the ranibizumab port delivery system (Susvimo) on a case-by-case basis.

How to choose a UK faricimab clinic in 2026

• Clinical leadership — a UK GMC specialist registered consultant ophthalmologist with documented medical retina fellowship, doing a high volume of intravitreal anti-VEGF therapy (typically 1,000 or more injections per year), with audit data on per-injection endophthalmitis rate (target less than 0.05 per cent), intra-ocular inflammation rate, and 1-year and 2-year BCVA outcomes available on request.
• Full medical retina imaging — swept-source or spectral-domain OCT macula, OCT angiography, fundus fluorescein angiography (FFA), indocyanine green angiography (ICG) — all available in-house, not contracted out, with same-visit imaging for time-critical decisions.
• CQC-registered clean-room or sterile minor procedure room with the latest report rated Good or Outstanding, with documented povidone iodine protocol, sterile technique, no-touch injection and audit of per-injection complication rates.
• Same-day initiation — ability to deliver the first injection on the day of diagnosis if clinically urgent.
• Treat-and-extend protocol — OCT-driven, evidence-based, individualised; not a fixed regimen.
• Honest evidence-based consent — written information about per-injection endophthalmitis, intra-ocular inflammation, rare retinal vasculitis with occlusion, and the realistic year-1 and maintenance-year treatment burden.
• Transparent itemised pricing — the invoice should split consultation, OCT, OCT-A, FFA / ICG (if performed), drug, procedure and post-injection check, with a year-1 budget projection.
• Continuity of care — the same consultant for consultation, all injections and follow-up; not a rotating team.
• Direct access — a published 24/7 number for postoperative concerns and a same-day clinic slot for endophthalmitis symptoms within 7 days of injection.
• Switch capability — the clinic should be able to switch between faricimab, aflibercept 2 mg, aflibercept 8 mg, ranibizumab and bevacizumab on a clinical basis, not on a drug-availability basis.

Frequently asked questions

How much does a private faricimab (Vabysmo) injection cost in the UK in 2026?

UK 2026 self-pay private faricimab injection costs 1,100 to 1,650 pounds per injection at CQC-registered London medical retina centres. The fee covers the consultant assessment, OCT imaging, the injection procedure, the drug and immediate post-injection check. A typical year-1 course of 7 to 8 injections totals 7,700 to 13,200 pounds; year 2+ maintenance of 4 to 6 injections per year is 4,400 to 9,900 pounds annualised.

What is faricimab and how is it different from other anti-VEGF injections?

Faricimab is a bispecific monoclonal antibody that simultaneously inhibits VEGF-A and angiopoietin-2 (Ang-2). VEGF-A drives neovascular growth; Ang-2 destabilises existing vasculature and amplifies inflammation. The dual mechanism allows safe extension of treatment intervals up to Q16 in around 60 per cent of patients by year 2 (TENAYA / LUCERNE). Aflibercept (Eylea), ranibizumab (Lucentis) and brolucizumab (Beovu) target VEGF-A only.

How often will I need faricimab injections?

Licensed schedule for wet AMD: 4 monthly loading doses, then treat-and-extend Q8 up to Q16 based on OCT. In TENAYA / LUCERNE at year 2, ~60 per cent of patients were on Q12 or Q16. A typical year 1 burden is 7 to 8 injections; year 2+ maintenance is 4 to 6 injections per year.

Does the NHS pay for Vabysmo?

Yes. NICE TA800 (wet AMD), TA799 (DMO) and further NICE guidance (RVO) recommend faricimab on the NHS. NHS care is delivered through hospital eye service medical retina clinics with structured treat-and-extend. Realistic UK 2026 waits from diagnosis to first injection are 1 to 4 weeks.

Faricimab vs aflibercept (Eylea or Eylea HD)?

Faricimab (Vabysmo, 6 mg) is a dual VEGF-A / Ang-2 antibody dosed Q8 to Q16 by treat-and-extend after 4 monthly loading. Aflibercept 2 mg (Eylea) is VEGF-A + PIGF dosed Q8 / treat-and-extend after 3 monthly loading. Aflibercept 8 mg (Eylea HD) is high-dose VEGF-A monotherapy dosed Q12 / Q16 by treat-and-extend after 3 monthly loading. BCVA outcomes are comparable across the three; faricimab and aflibercept 8 mg allow more patients to extend safely.

Is faricimab safe? What are the risks?

Procedural risks (any intravitreal injection): endophthalmitis 0.02 to 0.05 per cent per injection, traumatic cataract less than 0.1 per cent, retinal detachment less than 0.05 per cent, vitreous haemorrhage less than 0.1 per cent, transient IOP spike very common. Drug-specific: intra-ocular inflammation 1 to 2 per cent per patient course; rare retinal vasculitis with occlusion (at lower frequency than brolucizumab). Systemic anti-VEGF risks (ATEs) very low with intravitreal administration.

Will my private medical insurance cover faricimab?

In 2026 Bupa, AXA Health, Aviva, Vitality and WPA cover faricimab for licensed indications (wet AMD, DMO, BRVO / CRVO macular oedema) with pre-authorisation. Coverage includes consultant fee, OCT imaging, the injection procedure and drug. The clinical letter must document the diagnosis, OCT findings, BCVA, central retinal thickness and rationale for faricimab specifically.

Can faricimab be used for diabetic macular oedema or retinal vein occlusion?

Yes. Faricimab is licensed and NICE-approved for DMO (TA799) on the basis of YOSEMITE / RHINE, and for macular oedema secondary to BRVO / CRVO on the basis of BALATON / COMINO. UK 2026 private cost per injection is the same as for wet AMD.

How quickly will faricimab improve my vision?

Most patients notice partial improvement in distortion and central vision within 1 to 4 weeks of the first injection, with progressive macular drying on OCT over 4 to 12 weeks. Mean BCVA gain at year 1 in TENAYA / LUCERNE is ~+6 ETDRS letters; stable or improved BCVA in 80 to 90 per cent at year 1. Once subretinal fibrosis or macular atrophy is established, treatment can stabilise but rarely recovers vision — early diagnosis matters.

What happens at a faricimab injection appointment?

60- to 90-minute visit: vision, IOP, slit-lamp, OCT macula, OCT-A where indicated. If treatment is indicated, dilation, topical anaesthetic, povidone iodine prep, sterile drape, lid speculum. 30-gauge needle through the pars plana 3.5 mm posterior to the limbus; 0.05 mL (6 mg) faricimab injected into the vitreous. Immediate IOP and vision check. Topical antibiotic for 24 to 48 hours and 7-day endophthalmitis symptom warning.

Will I need faricimab for life?

Wet AMD is a chronic disease; most patients require lifelong intravitreal therapy with OCT monitoring at each visit. Treatment burden falls with treat-and-extend — ~60 per cent of TENAYA / LUCERNE patients on Q12 or Q16 by year 2. A small proportion (5 to 10 per cent) achieve long-lasting remission and can pause with 3-monthly OCT surveillance. Stopping without monitoring is associated with a high risk of vision loss.

Faricimab vs aflibercept 8 mg vs the port delivery system — which is right for me?

Faricimab (Vabysmo) is a 6 mg dual VEGF-A / Ang-2 antibody dosed Q8 to Q16; aflibercept 8 mg (Eylea HD) is high-dose VEGF-A monotherapy dosed Q12 / Q16; the ranibizumab port delivery system (Susvimo) is a surgically implanted refillable reservoir with 6-monthly refills. The decision is shared with the consultant. See our anti-VEGF wet AMD overview.

Should I switch from aflibercept or ranibizumab to faricimab?

Patients on aflibercept 2 mg or ranibizumab unable to extend safely (recurrent fluid at Q4 to Q6) are often switched to faricimab. Real-world evidence (Truckenbrod 2024, AAO 2024 / 2025) shows 40 to 60 per cent can extend safely on faricimab after switching. Protocol: 1 to 2 monthly loading injections of faricimab then treat-and-extend. The decision is made by the consultant medical retinologist on OCT and BCVA.

When can I drive after a faricimab injection?

Most patients drive the same or next day after a faricimab injection, once the injection bubble has cleared and vision has settled. The DVLA standard is binocular Snellen 6/12 with both eyes open and a horizontal visual field of at least 120 degrees; if the fellow eye is healthy, this is usually preserved. Confirm with the consultant if you are uncertain.

Methodology and sources

This UK 2026 patient pricing and pathway guide was prepared by the Eye Surgery Clinic editorial team and reviewed by a UK GMC-registered consultant ophthalmologist with medical retina subspecialty interest. Pricing reflects a CQC-registered UK medical retina sample audited against published 2024 to 2026 self-pay tariffs from the major UK intravitreal anti-VEGF providers. Clinical statements are anchored on:

• Heier JS, Khanani AM, et al. (TENAYA and LUCERNE Investigators). Efficacy, durability, and safety of intravitreal faricimab up to every 16 weeks for neovascular age-related macular degeneration (TENAYA and LUCERNE). Lancet 2022; 399(10326): 729-740
• Wykoff CC, Abreu F, et al. (YOSEMITE and RHINE Investigators). Efficacy, durability, and safety of intravitreal faricimab with extended dosing up to every 16 weeks in patients with diabetic macular oedema (YOSEMITE and RHINE). Lancet 2022; 399(10326): 741-755
• BALATON and COMINO phase 3 trials of faricimab in macular oedema secondary to BRVO and CRVO (2024)
• AVONELLE-X and RHONE-X open-label extension studies of faricimab in wet AMD and DMO
• NICE Technology Appraisal TA800 Faricimab for treating wet age-related macular degeneration (2022)
• NICE Technology Appraisal TA799 Faricimab for treating diabetic macular oedema (2022)
• NICE guidance for macular oedema secondary to retinal vein occlusion
• Royal College of Ophthalmologists Age-Related Macular Degeneration: Guidelines for Management
• American Academy of Ophthalmology Age-Related Macular Degeneration Preferred Practice Pattern
• EURETINA Treatment Recommendations for Neovascular AMD (latest update)
• Real-world evidence: Truckenbrod et al. 2024; AAO 2024 / 2025 retina subspecialty day proceedings
• Care Quality Commission (CQC) inspection reports for major UK medical retina units
• General Medical Council (GMC) Good Medical Practice and consent guidance

This page is editorial and educational. It is not personalised medical advice. Faricimab suitability can only be confirmed by an in-person medical retina consultation with OCT and OCT angiography.

Book your UK faricimab (Vabysmo) consultation

Speak directly to a UK GMC-registered consultant ophthalmologist with medical retina subspecialty interest. Same-week consultation slots are usually available. Slit-lamp, OCT macula, OCT angiography and (where indicated) FFA and ICG included. Same-day first injection on a clinical urgency basis. Confidential, no-obligation review of whether faricimab (Vabysmo), aflibercept 2 mg (Eylea), aflibercept 8 mg (Eylea HD), ranibizumab (Lucentis) or the port delivery system (Susvimo) is right for you.

Related reading: Private anti-VEGF wet AMD injections London · Wet AMD condition guide · Dry AMD condition guide · Wet vs dry AMD treatment options UK 2026